Future Asset New ETF Effect, Biotech Stock Prices "Strong"

The new listed index fund (ETF) for future asset management, “TIGER Technology Transfer Bio Active,” was listed on the Korean Exchange on the 17th. The stocks included in this ETF performed strongly, especially some biotech companies like RIGECHEM BIO, which saw significant gains.

On that day, RIGECHEM BIO rose 4.48% compared to the previous trading day, closing at 210,000 Korean won. ABL Bio, Samchundang Pharmaceutical, and Hanmi Pharmaceutical also increased by 2.14%, 1.23%, and 4.00%, respectively, attracting investor attention. Analysts believe that the stock price increase was driven by improved investment supply and demand expectations following the ETF’s listing.

The “TIGER Technology Transfer Bio Active” ETF is based on the “KRX Technology Transfer Bio” index released by the Korea Exchange, primarily investing in domestic biotech transfer companies listed on KOSDAQ. The initial portfolio of this ETF includes biotech firms such as RIGECHEM BIO, OliX, and ABL Bio, which together account for approximately 86.8% of the ETF’s total weight.

Additionally, the ETF also includes stocks from traditional pharmaceutical companies like Samchundang Pharmaceutical, Hanmi Pharmaceutical, ST Pharm, and Celltrion. Including these companies reflects a strategy of pursuing both stability and growth in future asset operations. Recently, various active ETFs based on the KOSDAQ market have been launched, and the market has responded positively to the inclusion of these stocks, observing their benefits.

This trend, combined with technological innovation and market growth in the biotech and medical fields, indicates that investment flows into biotech-related stocks and ETFs may continue to grow. Investors are expected to increasingly focus on this sector while balancing risk and return.